https://orcid.org/0000-0002-6739-0387
References
- Genovese G, Moltrasio C, Cassano N, et al. Pustular psoriasis: from pathophysiology to treatment. Biomedicines. 2021;9(12):1746.
- Papp K, Gordon K, Thaçi D, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379(14):1313–1321.
- Armstrong A, Gooderham M, Warren RB, et al.POS1042 - Efficacy and safety of Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, compared with placebo and apremilast in moderate to severe plaque psoriasis: results from the phase 3 POETYK PSO-1 STUDY. Ann Rheum Dis. 2021;80(Suppl 1):795–796.
- Warren R, Armstrong A, Gooderham M, et al. Abstract No 2857 - deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy results from the phase 3 POETYK PSO-1 and POETYK PSO-2 Trials. EADV 30th Congr. 2021 [cited 2022 Sep 12]. Available from: https://s3.eu-central-1.amazonaws.com/cst.eadv/eadv2021/abstracts/26128.html.pdf
- Bissonnette R, Poulin Y, Zhou Y, et al., Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial. Br J Dermatol. 2012;166(4):853–860.
- Robbins K, Bissonnette R, Maeda-Chubachi T, et al. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis. J Am Acad Dermatol. 2019;80(3):714–721.
- Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385(24):2219–2229.
- McCulloch T. FDA approves arcutis’ zoryve (roflumilast) cream 0. 3% for the treatment of plaque psoriasis in individuals age 12 and older. Arcutis Biotherapeutics. Published July 29, 2022. cited 2022 Aug 22. Available from: https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-cream-0-3-for-the-treatment-of-plaque-psoriasis-in-individuals-age-12-and-older/
- Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of roflumilast cream for chronic plaque psoriasis. N Engl J Med. 2020;383(3):229–239.
- Lebwohl M, Kircik LH, Moore A, et al. Once-daily roflumilast cream 0.3%, a potent phosphodiesterase-4 inhibitor, provided safe and effective treatment of psoriasis in the DERMIS-1 and DERMIS-2 phase 3 trials [abstract 2063]. EADV 30th Congress; 2021. *Effects of roflumilast in phase III trials for the treatment of psoriasis
- Bachelez H, Choon SE, Marrakchi S, et al., Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431–2440.
- GlobeNewswire. AnaptysBio presents updated data from imsidolimab phase 2 GALLOP trial in generalized pustular psoriasis 2021 [cited 2022 Sep 12]. Available from: https://www.globenewswire.com/news-release/2021/10/02/2307446/0/en/AnaptysBioPresents-Updated-Data-From-Imsidolimab-Phase-2-GALLOPTrial-in-Generalized-Pustular-Psoriasis.html
- Gudjonsson JE, Randazzo B, Zhou J, et al. Imsidolimab in the treatment of adult subjects with generalized pustular psoriasis: design of a pivotal phase 3 clinical trial and a long-term extension study. Presented at: the 2022 American Academy of Dermatology Annual Meeting, Boston. 2022 [cited 2022 Mar 25–29]. Abstract/Poster 34617
- Barry K, Zancanaro P, Casseres R, et al. Concomitant atopic dermatitis and psoriasis - a retrospective review. J Dermatolog Treat. 2021;32(7):716–720.
- Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. Expert Opin Biol Ther. 2020;20(6):665–672.